A Study of MA-0217 (ASP1128) in Healthy Adult Subjects and Healthy Elderly Subjects
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 102
- Registration Number
- NCT04742517
- Locations
- 🇺🇸
Parexel Early Phase Clinical Unit - Los Angeles, Glendale, California, United States
A Study of ASP8302 in Participants With Underactive Bladder
- First Posted Date
- 2018-10-11
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 135
- Registration Number
- NCT03702777
- Locations
- 🇩🇪
Site DE49001, Duisburg, Germany
🇩🇪Site DE49002, Duisburg, Germany
🇩🇪Site DE49004, Gronau, Germany
A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis
Phase 2
Completed
- Conditions
- Bladder Pain SyndromeInterstitial Cystitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-09-13
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 119
- Registration Number
- NCT03282318
- Locations
- 🇧🇪
Site BE32001, Leuven, Belgium
🇨🇿Site CZ42002, Plzen, Czechia
🇩🇪Site DE49003, Duisburg, Germany
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP7713 in Healthy Non-Japanese Adult and Elderly Subjects and Healthy Japanese Adult Subjects
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 40
- Registration Number
- NCT03108755
- Locations
- 🇬🇧
Site GB44001, Harrow, Middlesex, United Kingdom
A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function
- First Posted Date
- 2016-11-16
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 34
- Registration Number
- NCT02965040
- Locations
- 🇩🇪
Site DE49001, Munchen, Germany
🇬🇧Site GB44001, Liverpool, United Kingdom
A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2016-06-09
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 268
- Registration Number
- NCT02794792
- Locations
- 🇷🇺
Site RU70011, Moscow, Russian Federation
🇷🇺Site RU70005, Moscow, Russian Federation
🇷🇺Site RU70003, Moscow, Russian Federation
A Study To Assess The Efficacy And Safety Of Bismuth Tripotassium Dicitrate (De-Nol) In Combination With Pantoprazole And Pantoprazole Monotherapy In Treatment Of Subjects With Nonsteroidal Anti-Inflammatory Drugs (NSAID)-Induced Gastropathy
Phase 4
Terminated
- Conditions
- NSAID-induced Gastropathy
- Interventions
- Drug: bismuth tripotassium dicitrate
- First Posted Date
- 2016-06-02
- Last Posted Date
- 2017-09-21
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 9
- Registration Number
- NCT02788123
- Locations
- 🇷🇺
Site RU70001, Moscow, Russian Federation
🇷🇺Site RU70008, Saint-Petersburg, Russian Federation
🇷🇺Site RU70012, Saint-Petersburg, Russian Federation
Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 91
- Registration Number
- NCT02751931
- Locations
- 🇦🇺
Site AU61002, Randwick, New South Wales, Australia
🇧🇪Site BE32004, Edegem, Belgium
🇧🇪Site BE32001, Gent, Belgium
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects
Phase 1
Completed
- Conditions
- Healthy SubjectsPharmacokinetics of ASP6294
- Interventions
- Drug: ASP6294 IntravenousDrug: ASP6294 SubcutaneousDrug: Placebo IntravenousDrug: Placebo Subcutaneous
- First Posted Date
- 2016-02-15
- Last Posted Date
- 2017-01-10
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 74
- Registration Number
- NCT02681861
- Locations
- 🇬🇧
Site GB44001, Harrow, United Kingdom
EC905 Pharmacokinetic Profile Study
Phase 1
Completed
- Conditions
- HealthyPhase 1Benign Prostatic HyperplasiaLower Urinary Tract Symptoms
- Interventions
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2015-12-18
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 46
- Registration Number
- NCT02634489
- Locations
- 🇳🇱
Site NL1, Zuidlaren, Drente, Netherlands